The aim of this study was to develop and optimize a nanoparticulate carrier based on polymeric blends of cellulose acetate butyrate (CAB) and poly(vinyl pyrrolidone) (PVP) to enhance dissolution profile of an antiviral drug. These nanoparticles are studied by means of X-ray powder diffraction, FTIR and DSC while the morphology evaluated using SEM analysis. Drug-loaded nanoparticles were produced in spherical shape with sizes and encapsulation efficiency ranging from 322 to 434 nm and 50% to 70% respectively. The effects of different CAB/PVP ratios, concentration of drug and emulsifier on the nanoparticle size, drug encapsulation and in vitro release were studied in detail. In vitro release along with mechanism and kinetics were studied in different pHs indicating that the release of drug from nanoparticles was pH-responsive. All the nanoparticles displayed a slowed release pattern with the reduced burst release. The mechanism and kinetics of the drug delivery system was also systematically studied using various models such as zero order, first order, Higuchi model and Korsmeyer-Peppas. The results indicate that the new CAB/PVP nanoparticles have a promising potential to serve as an antiviral controlled delivery system. ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
The importance of biocompatible and biodegradable polymers is continuously increasing in pharmaceutical applications, to prepare new controlled drug delivery systems (Raval et al., 2014) . For such systems size and morphology of the polymer matrix assume an extremely important role in the drug release and pharmacokinetics. Polymer physical blends are frequently used as excipients in the pharmaceutical field to obtain controlled drug delivery systems due to their versatility (Karnichi et al., 1995; Nerurkar et al., 2005; Patel and Patel, 2007; Raffin et al., 2007) . Mixed polymer drug delivery systems must possess the appropriate morphology to facilitate the required drug release profile (Karavas et al., 2006) . Broad ranges of system characteristics and thus, drug release patterns can be provided simply varying the polymer blend ratio (Lecomte et al., 2005) , that could not be obtained by individual polymers (Sahoo et al., 2010) . This fact is demonstrated by the publication of numerous patents and research papers and their utilization in new products in the market place (Abbaspour et al., 2008; Alkhatib and Sakr, 2003) .
Recently, polymeric nanoparticles (NPs) are extensively and intensively studied and are considered as one of the most promising drug delivery systems (Duan et al., 2010) . The delivery of pharmaceuticals can be improved by novel drug delivery systems using therapeutic colloidal nanocarriers, including polymeric nanoparticles (Ishiharaa et al., 2009) . Several polymeric nanoparticulate systems have been prepared and characterized based on both natural and synthetic biodegradable polymers. The inherent shortcomings of conventional drug delivery and the potential of nanoparticles as drug delivery systems have offered tremendous scope for researchers in this field and are fast moving from concept to reality. The nanoparticles have the ability for both controlling the release and protecting the loaded drug against its degradations; therefore, they may improve the plasma half life of the drug (Mainardes et al., 2010) . All of these benefits can contribute to the reduction of dose and dosing frequency, thereby reducing the side effects and improving the patient compliance (Bala et al., 2004) .
Acyclovir (9-[2-hydroxyethoxymethyl]-9H-guanine, (ACY) is an acyclic analog of the natural nucleoside 2 0 -deoxyguanosine, most widely used drug for infections such as cutaneous herpes, genital herpes, chicken pox, and varicella zoster infections. ACY has a short biological half life of 2-3 h and low bioavailability of 10-20% . Due to a short biological half-life, it is considered as an ideal candidate for controlled drug delivery. Various approaches are made to improve the concentration of ACY in the plasma over the extended period of time there by reducing the drug dosage and unwanted toxic effects.
In this study, the objective was to design and characterize a nanoparticulate carrier system for ACY to obtain a high concentration of the drug at infection site with prolonged residence providing a controlled release profile, reduction of side effects associated with systemic administration along with better control over biodistribution. For this reason two polymers with different properties such as hydrophobicity (cellulose acetate butyrate (CAB)) and high hydrophilicity (poly(vinyl pyrrolidone) (PVP)) were selected. Several reports have discussed the interaction of PVP with other polymers, surfactants, and adsorbents (Sen and Yakar, 2001) .
The nanoparticles were prepared by modified solvent evaporation/extraction technique in combination with high speed homogenizer and the main experimental factors influencing the characteristics of nanoparticles were investigated to optimize the preparation method. Poly vinyl alcohol (PVA) was used as an emulsifier. The main advantage of emulsifier in process is the instantaneous and reproducible formation of nanometric, monodispersed nanospheres exhibiting a high drug loading capacity (Derakhshandeh et al., 2007) . Enhancement or retardation of ACY release rate from the nanoparticles can be achieved by adjusting the ratio of two polymers; CAB and PVP, concentration of the drug and emulsifier. The physicochemical properties of the nanoparticles were characterized as well.
Experimental

Materials
Acyclovir was received as a gift sample from Cadila Pharmaceuticals Ltd, (Ahmedabad, India). Cellulose acetate butyrate of different molecular weights (12,000 Da), poly(vinyl pyrrolidone) (MW about 3.6 · 105) and poly vinyl alcohol (MW 85,000, degree of hydrolysis 95%) were purchased from Aldrich (Milwaukee, WI, USA). All chemicals used were of analytical grade and used as received. Double-distilled water was used throughout the work.
Preparation of polymeric binary blend nanoparticles
Nanoparticles were prepared by solvent evaporation/extraction technique (Mu and Fenga, 2002) with slight modification. The objective of the present study was to understand the effect of polymer blend composition, drug loading and emulsifier concentration on particle formation, particle morphology and release behavior leading to lowest effective dose preparation of ACY. CAB and PVP were dissolved in organic solvent mixture consisting of dichloromethane/acetone (9:1, v/v, 10 mL). ACY was dissolved in water (2 mL) and added in the above solution. This mixture was sonicated using a microtip probe sonicator set at 55W of energy output (XL 2002 SonicatorÒ ultrasonic liquid processor) for 1 min to produce the water-in-oil emulsion. The resulted solution was slowly dropped into 50 ml PVA (0.5-1% w/v) as an external phase. During this process, the mixture was homogenized using a high speed homogenizer (CHG-15A, Daihan Scientific Co. Ltd, Korea), at agitation speed of 20,000 rpm and kept on icedwater bath. The formed water-in-oil-in-water (W/O/W) emulsion was gently stirred at room temperature for 3 h to evaporate the organic solvents. The nanosuspensions were then centrifuged at 14,000 rpm (Remi Elecktrotechnic Ltd, Vasai, Maharashtra, India) 20°C for 20 min. Supernatants from previous step were further centrifuged to ensure that all the dispersed nanoparticles were collected. The collected nanoparticles were washed (3 times) with distilled water using previously described centrifugation approach. The final product was stored in a vacuum desiccator at room temperature.
Determination of drug contents and loading efficiency
To determine drug contents, 5 mg of nanoparticles was dissolved in 5 ml of DCM and then 5 ml of deionized water was added. This mixture was stirred magnetically for 6 h and then 1 ml of water phase was taken to measure drug concentration. Absorbance of aqueous phase was measured at 252 nm (Tao et al., 2009) 
Amorphous polymeric binary blend pH-responsive nanoparticles for dissolution enhancement S169 2.4. Determination of particle size Particle size was measured by dynamic laser light scattering model Halos-BF (Symantec, Germany). Size of the completely dried nanoparticles of different formulations was measured by dry sample technique using a dry sample adapter. The completely dried particles were placed on the sample tray with an inbuilt vacuum under a compressed air system, which was used to suspend the particles. The laser obscuration range was maintained between 0.1 and 875 lm. The volume mean diameter (VMD) was recorded. After the measurement of particle size of each sample, the dry sample adopter was cleaned thoroughly to avoid cross contamination. Each batch was analyzed in triplicate, but average values were considered in data analysis. The polydispersity index (PDI) which is a dimensionless number indicating the width of the size distribution, having a value between 0 and 1 (0 being for monodispersed particles) was also obtained.
Particle morphology
The surface morphology and surface characteristics of samples were studied by scanning electron microscopy (SEM). The powder samples were dispersed in water, and were dropped onto metal stubs and allowed to dry in air under ambient conditions. Each sample was coated with gold under vacuum prior to examination by SEM (JSM-5410, Jeol, Japan). The surface of samples was scanned using a gaseous secondary electron detector (working pressure: 0.8 torr, acceleration voltage: 30 kV, XL 30 (Philips, Eindhoven, Netherlands)).
Fourier transform infrared spectra
To investigate the possible chemical interactions between ACY and the biodegradable polymers, the spectra were recorded for CAB, PVP, placebo nanoparticles, drug-loaded nanoparticles and pristine ACY using Fourier transform infrared spectroscopy (FTIR; Spectrum GX, Perkin Elmer, Chicago, USA). Polymer samples were crushed to make KBr pellets under a hydraulic pressure of 300 kg/cm 2 . FTIR spectra were taken in the wavelength region between 400 and 4000 cm À1 and the resolution of 0.15 cm À1 at scan speed of 10 scan/s.
X-ray powder diffractogram
Pristine ACY, placebo and ACY-loaded nanoparticles were evaluated by powder XRD technique to determine the crystallinity of drug. X-ray diffraction (XRD) patterns were obtained using Philips X-ray diffractometer (X pert), with voltage of 40 kV, current of 40 mA and Cu a-radiation source in the range of 3-40°of 2h with 1 s of scan time. All experiments were performed at room temperature.
Differential scanning calorimetry
Differential scanning calorimetry (DSC) curves were obtained for CAB, PVP, placebo nanoparticle, drug-loaded nanoparticle and pristine ACY with DSC-Pyris-1 (Perkin Elmer). The analysis was performed with a heating range of 50-300°C and at a rate of 10°C/min.
Drug release study
To study in vitro drug release, the nanoparticles (all containing 5 mg of ACY) were placed in the vessels containing 100 ml of phosphate buffer solution (PBS pH 1.2 and 7.4) as the dissolution medium. The vessels were incubated at 37°C with continuous orbital mixing on a shaker (Lab-term, sic/incu shaker/01 Kuhner, Switzerland) at 50 rpm. The release medium was exchanged everyday to maintain the sink condition. At predetermined time schedule, release medium was taken and concentration of released drug was measured with UV-spectrophotometer (SP-3000Plus, Tokyo) at 252 nm. The volume withdrawn was replenished with an equal volume of fresh and pre-warmed PBS 37°C to maintain the constant volume. All experiments were done in triplicate.
Release kinetics
Data obtained from in vitro drug release study, were fitted to various kinetic equations to find out the mechanism and kinetics of drug release from nanoparticles . The model giving a correlation coefficient close to unity was taken as order of release. The kinetic equations used were zero order equation, first order equation and Higuchi model.
where k 0 is the zero-order rate constant expressed in units of concentration/time and t is the time.
where k 1 is the first order constant.
where k h is the Higuchi constant reflecting the design variables of the system. The following plots were made; Q t vs. t (zero order kinetic model), log(Q 0 ÀQ t ) vs. t (first order kinetic model) and Q t vs. square root of t (Higuchi model) (Higuchi, 1963) , where Q t is the total amount of drug released at time t and Q 0 is the initial amount of the drug present in the nanoparticles. The rate constants were calculated for the respective models. Further, in order to define a model which will represent a better fit for the formulation, the first 60% drug release data were fitted in Korsmeyer-Peppas (Korsmeyer et al., 1983) 
where k is the kinetic constant and n is the diffusion exponent, a measure of the primary mechanism of drug release.
Results and discussion
3.1. Drug loading, particle size and morphology
Size of particle can play a vital role as it can directly affect the physical stability, biodistribution, cellular uptake and the drug release. In general, the smaller the particle size, the better the performance of the nanoparticles (Rieux et al., 2006) . The size of nanoparticles depends on the % PVP content, amount of drug loaded in the polymer blended matrix, and concentration of emulsifier. S170 D.R. Naik and J.P. Raval
The sizes of the nanoparticles are in the range of 322-434 nm. The results in Table 1 shows that the size of nanoparticles decreases with the increase in the amount of PVP in the polymer blended matrix. It is observed that particle size of B1 (10% (w/w), PVP) is larger than that of B2 (20% (w/w), PVP), similarly the particle sizes of B3, B5 and B7 are larger than those of B4, B6 and B8 formulations. This variation in size was due to the fact that viscosity of polymer solution decreases with higher amounts of PVP in the polymer blended matrix so, smaller emulsion droplets were formed, resulting in smaller nanoparticles. Thus as the hydrophilicity of the polymer increases, the interaction amongst the polymer, oil phase and aqueous phase changes accordingly.
Further, the results indicated that the particle size also depended on amount of drug loaded. The formulations containing 20% drug (B1, B2, B5 and B6) produce lower particle sizes than those containing 40% of drug (B3, B4, B7 and B8). This can be explained by the fact that a greater amount of drug results in a more viscous dispersed phase which causes gathering of more of drug particles during the nanoparticle formation.
Another interesting observation is that particle size shows dependence on the emulsifier concentration. Particle size decreases with increasing extent of emulsifier (Mainardes and Evangelista, 2005) . The results in Table 1 shows that particle size of B5, B6, B7 and B8 is smaller compared to B5 B2, B3 and B4. This is easy to understand: the emulsifier remains at the interface separating the oil and water phases. Smaller particles have a larger total surface area and thus need more emulsifier. Too much emulsifier may result in particle aggregation and too little emulsifier would result in no nanoparticles formation (Mu and Feng, 2003) . SEM studies revealed a spherical shape of resultant nanoparticles (Fig. 1) .
Encapsulation efficiency
It is important to achieve high encapsulation efficiency (EE), for an effective formulation. The present study found that drug encapsulation efficiency in nanoparticles was influenced by different experimental parameters such as drug-polymer ratio, polymer blend composition and concentration of emulsifier. Results in Table 1 indicate that, % EE increases by increasing the amount of PVP. This is due to the loss of hydrophilic polymer from dispersed phase into aqueous continuous phase because of its higher solubility in water. As a result encapsulation efficiency could be enhanced by increasing the concentration of PVP in the formulation. Amorphous polymeric binary blend pH-responsive nanoparticles for dissolution enhancement S171
The drug encapsulation efficiency shows dependence on drug loading, possibly being one of the most significant factors. As seen in Table 1 , formulations containing a high amount of drug exhibit higher values of EE. This can be explained by the fact that, when the drug loading was high, the more number of drug particles were accumulated inside the free volume spaces of the matrices and when the drug loading was low, the amount of drug entrapped in the nanoparticles would decrease. Furthermore, the % EE also depended upon the concentration of emulsifier. As the concentration of emulsifying agent increases, EE also increases due to the formation of a rigid network, thereby retaining more drug particles during formulation. Moreover, it could be observed that higher concentrations of emulsifier i.e. more than 1% cause aggregation of nanoparticles during the fabrication process where as the shape of the nanoparticles obtained was not spherical.
Polymer-drug interaction analysis using FTIR spectroscopy
Interaction between the drug and polymers commonly leads to identifiable changes in the FTIR patterns (Bhise et al., 2008) . FTIR spectra were compared to find any change in frequency of functional group in nanoparticles with respective functional group of the drug. FTIR spectra of PVP, CAB, placebo nanoparticles, drug loaded nanoparticles and ACY are demonstrated in Fig. 2 .
FTIR spectrum of PVP shows the presence of stretching adsorption peaks of -C‚O (1647.21 cm À1 ), -C-N-(1317.38 cm À1 ), -C-H-(2951.09 cm À1 ) and water (3649.32 cm À1 ). FTIR spectrum of CAB, shows the presence of -C-Hstretching vibrations (2937.59 cm À1 ) and -O-H (3641.23 cm À1 ). The placebo nanoparticles gave the characteristic peaks of both PVP and CAB. FTIR spectrum of ACY, shows the presence of N-H (3439.08 cm À1 ), -O-H (3296.35 cm À1 ), C-H (3130.47 cm À1 ), C‚O (1691.57 cm À1 ) stretching vibrations. There is no significant difference in characteristic peaks of pristine drug and drug-loaded nanoparticles suggesting drug stability during encapsulation process. This shows the absence of any chemical interactions between drug and polymer.
X-ray diffraction studies
XRD is frequently used to analyze degree of sample crystallinity. X-ray diffractograms of placebo nanoparticles, drug loaded nanoparticles and pristine ACY were studied and are demonstrated in Fig. 3 . As indicated by X-ray examinations, there was no clear peak in the X-ray diffractograms for the amorphous polymer. The intact ACY manifested distinct peaks that are characteristics of its crystalline nature. However, distinct diffraction peaks have disappeared in the ACY-loaded nanoparticles, but only peaks observed in placebo matrix are observed signifying a drug amorphization or its solvation in the amorphous carrier. XRD peak depends on the crystal size, but in the present study, for all drug-loaded matrices, characteristic peak of ACY was overlapped with the noise of the polymer (Raval et al., 2014) . This suggests that even after encapsulation, blend matrix shows amorphous nature and hence, it is difficult to study the crystallinity of ACY at the detection limit of the crystal size. XRD data thus indicate that drug is dispersed molecularly in the polymer matrix (Jingou et al., 2011) .
Differential scanning calorimetry
DSC has been extensively used calorimetric technique to characterize the physical state of drug in the polymeric matrix. Fig. 4 depicts the DSC thermogram of PVP, CAB, placebo nanoparticles, drug loaded nanoparticles and pristine ACY. CAB is mainly amorphous with a poor crystalline part which shows a broad peak at 146°C. The thermogram of PVP showed any characteristic peaks. Also, placebo nanoparticles showed no peak and indicated the amorphous nature of carrier particles. The DSC thermogram of ACY exhibited a single sharp endothermic peak at 252.1°C corresponding to its melting transition temperature. This sharp endothermic peak indicated that the intact ACY was in crystalline anhydrous state. The thermogram of the drug loaded nanoparticles showed no such characteristic peak, owing to the decreased crystallinity in the formulations and/or drug solvation in the amorphous carrier as well as solid state interaction induced by heating. Thus, it revealed that the drug was uniformly dispersed at the molecular level in nanoparticles.
DSC results demonstrated consistency with the findings obtained from X-ray analysis. Concisely, the PXRD and DSC studies verified a decrease of drug crystallinity in the nanoparticles. 3.6. In vitro release The drug delivery system was developed for the purpose of bringing, up taking; retaining, releasing, activating, localizing and targeting the drugs at the right time period, dose and place (Sahoo et al., 2010; Rathbone et al., 1999) . The biodegradable polymer can contribute largely to this technology by adding its own characters to the drugs. In the present study, a medium molecular weight CAB was blended with PVP to prepare the blend biodegradable polymer system. In vitro release experiments of ACY from the polymer blend nanoparticles were performed in simulated gastric (pH 1.2) conditions for first 4 h and continued in intestinal (pH 7.4) conditions. To avoid erroneous results due to sudden temperature changes, the dissolution media (phosphate buffers) were gradually warmed to 37°C, at which all the in vitro experiments were performed. Here, in vitro release data are discussed in terms of effect of polymer blend composition, drug loading and concentration of emulsifier. Average % cumulative release vs. time plots for drug-loaded nanoparticles of all the formulations are displayed in Fig. 5(a-c) , respectively, to examine the effect of polymer blend composition, drug loading and concentration of emulsifier. 
Effect of polymer blend composition
The nature, morphology and properties of the polymers as well as the blend composition in the systems are the important factors for controlling ACY release from the polymer blend nanoparticles. The effect of polymer blend ratio for formulations B1, B2, B3 and B4 is displayed in Fig. 5(a) .
The polymer blend formed remains stable in the dissolution media and triggers the release of ACY drug showing slight burst release at acidic pH, with controlled slow release in alkaline pH media. Such initial burst release can be beneficial to improve the penetration of drug and to achieve the effective plasma concentration after administration of ACY, while sustained release delivers the drug over a prolonged period of time. The observed burst effect was due to the fast nanoparticle degradation, occurred due to the readily degradable PVP polymer, which was then followed by a slower release from the CAB sections (Nath et al., 2009) . Another reason for burst effect was the high solubility of drug in acidic pH. After 7 days of slow release, a step functional release is observed with no drug release, thereby showing a final level off. The complete release of ACY was achieved between 5 and 7 days for all the formulations.
Our investigations further revealed that the polymer blend matrices with a higher content of hydrophilic PVP degraded faster since degradation takes place more rapidly in PVP. So, higher amounts of PVP, released higher amounts of drug and vice versa. The results showed that % cumulative release was higher for batches containing higher amounts of PVP in polymer blend.
Effect of drug loading
The release profiles of drug from the blend nanoparticles at different amounts of drug loadings are displayed in Fig. 5(b) . Results of the release data revealed that formulations containing the highest amount of drug (40%) displayed fast and higher release rates compared to those formulations containing a small amount of drug loading. The increase in the drug content causes increase in the amount of drug close to the surface and in the core of nanoparticles. The increased initial burst effect is caused by drug content which is closer to the surface of the nanoparticle whereas the drug in the core of nanoparticles is responsible for a prolonged drug release from the polymer (Dhanalekshmi et al., 2010) . When the amount of drug loading is less, the drug release rate become slow, as a less number of drug molecules have more free void spaces available to transport.
Effect of concentration of emulsifier
PVA appeared to be the most suitable emulsifier in reducing aggregation between nanoparticles which suspends immediately after formation. Nanoparticles were prepared at two different emulsifier concentrations, i.e. 1% and 0.5%. As displayed in Fig. 5c , formulation B1 exhibits higher release than B5; similarly, B3 exhibits higher release than B7. Notice that B5, B6, B7 and B8 contain higher concentrations of PVA (1%) and hence, these are more rigid than B1, B2, B3 and B4.
Release kinetics
In order to determine the release model which best describes the pattern of drug release, the in vitro release data were fitted to models representing zero-order, first-order, and Higuchi's square root of time. The zero order release models describe, the systems, where the rate of drug release is independent of its concentration. The first order release models, describe the systems, where the rate of drug release is dependent of its concentration. Higuchi model describes the rate of drug release from an insoluble polymer matrix as a square root of time dependant process. To examine the mechanism of release the data were fitted to Korsmeyer-Peppas model. The release constants were calculated from the slope of the appropriate plots, and regression coefficient (R 2 ) was determined by linear regression analysis and the results are tabulated in Table 2 . Based on the results, ACY release from nanoparticles followed Higuchi equation and related correlation coefficients were better than both zero order and first order kinetics. Thus the ACY release from the nanoparticles was proportional to square root of time. This indicates that the drug release is controlled by diffusion of the drug through the pores for all the formulations.
In all trials, drug release mechanism was studied by applying Korsmeyer-Peppas model. According to Korsmeyer-Peppas, a value of the exponent, n = 0.5, 0.5 < n < 1, n = 1.0 indicates Fickian diffusion, non-Fickian diffusion and purely relaxation-controlled delivery which is referred to as Case II transport, respectively. The results shown in Table 2 . indicate Table 2 Release rate constants k x , correlation coefficients (R 2 ) and diffusion exponent (n) calculated after fitting the release profiles obtained using different mathematical models. the values of diffusional exponent, n for the nanoparticles lesser than 0.5 indicating a fickian release (Budhian et al., 2008) .
Conclusion
Cellulose acetate butyrate is a hydrophobic biodegradable polymer whereas poly(vinyl pyrrolidone) is a hydrophillic biopolymer. The blending of the two polymers has been carried out varying the proportion and it was found that the blend so obtained proved to be a better drug carrier. SEM, Differential scanning calorimetry, Fourier-transform infrared spectroscopy and X-ray diffraction studies showed chemical stability and intactness of entrapped drug in the nanoparticles. The study demonstrated that it is possible to adjust the rate of drug release by varying the polymer blend composition, drug loading and concentration of emulsifier to attain predictable release rates from nanoparticles. According of these findings, formulation of the ACY-loaded cellulose acetate butyrate/poly(vinyl pyrrolidone) binary blend nanoparticles was able to improve the physicochemical characteristics of the drug and possibly will increase the anti-retroviral effects of drug following its oral administration.
